Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3042]

A patient-reported questionnaire may eliminate the need for an ophthalmic exam...

Prof Evangelos Terpos - University of Athens, School of Medicine, Athens, Greece

A patient-reported questionnaire may eliminate the need for an ophthalmic exam before belantamab mafodotin dosing in TI NDMM ( Prof Evangelos Terpos - University of Athens, School of Medicine, Athens, Greece )

ASCO 2024: Lung cancer highlights

Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas...

ASCO 2024: Lung cancer highlights ( Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom )

EHA 2024: Multiple myeloma roundup

Dr Claudio Cerchione - IRCCS, Meldola, Italy

EHA 2024: Multiple myeloma roundup ( Dr Claudio Cerchione - IRCCS, Meldola, Italy )

Whole body-MRI and fluorine 18 fluorodeoxyglucose PET/CT shows promising...

Dr Claudio Cerchione - IRCCS, Meldola, Italy

Whole body-MRI and fluorine 18 fluorodeoxyglucose PET/CT shows promising diagnostic accuracy in multiple myeloma patients ( Dr Claudio Cerchione - IRCCS, Meldola, Italy )

ATRA-ATO regimen with idarubicin could become the new standard of care in high...

Dr Uwe Platzbecker - University Hospital Leipzig, Leipzig, Germany

ATRA-ATO regimen with idarubicin could become the new standard of care in high-risk acute promyelocytic leukaemia ( Dr Uwe Platzbecker - University Hospital Leipzig, Leipzig, Germany )

More effective treatment options required for patients with MM post...

Dr Claudio Cerchione - IRCCS, Meldola, Italy

More effective treatment options required for patients with MM post lenalidomide exposure ( Dr Claudio Cerchione - IRCCS, Meldola, Italy )

Ibrutinib and venetoclax continue to provide benefits for patients with chronic...

Dr Paolo Ghia - Università Vita-Salute San Raffaele, Milan, Italy

Ibrutinib and venetoclax continue to provide benefits for patients with chronic CLL and SLL ( Dr Paolo Ghia - Università Vita-Salute San Raffaele, Milan, Italy )

Combination of zanubrutinib and venetoclax shows promise in high-risk TN CLL...

Dr Alessandra Tedeschi - Niguarda Cancer Center, Milan, Italy

Combination of zanubrutinib and venetoclax shows promise in high-risk TN CLL/SLL with del(17p) and/or TP53 mutation ( Dr Alessandra Tedeschi - Niguarda Cancer Center, Milan, Italy )

Isatuximab in combination with pomalidomide and dexamethasone shows promising...

Prof Evangelos Terpos - University of Athens, School of Medicine, Athens, Greece

Isatuximab in combination with pomalidomide and dexamethasone shows promising efficacy in 2nd line RRMM ( Prof Evangelos Terpos - University of Athens, School of Medicine, Athens, Greece )

3 year follow-up shows durable long-term RFS and DMFS benefit with mRNA-4157...

Dr Meredith McKean - Sarah Cannon Research Institute, Nashville, USA

3 year follow-up shows durable long-term RFS and DMFS benefit with mRNA-4157 plus pembrolizumab in resected melanoma ( Dr Meredith McKean - Sarah Cannon Research Institute, Nashville, USA )

PD-1–refractory advanced melanoma: how do we get to the finish line?

Dr Meredith McKean - Sarah Cannon Research Institute, Nashville, USA

$PD-1–refractory advanced melanoma: how do we get to the finish line? ( Dr Meredith McKean - Sarah Cannon Research Institute, Nashville, USA )$

Immunotherapy significantly increases the number of patients free from bowel...

Dr Kai-Keen Shiu - UCL Cancer Institute, London, UK

Immunotherapy significantly increases the number of patients free from bowel cancer ( Dr Kai-Keen Shiu - UCL Cancer Institute, London, UK )

More from ecancer